The latest price target for Histogen Inc COM NEW (OTC:HSTO) was reported by HC Wainwright & Co. on March 29, 2022. The analyst firm set a price target for $1.50 expecting HSTO to rise to within 12 months (a possible 597.67% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Histogen Inc COM NEW (OTC:HSTO) was provided by HC Wainwright & Co., and Histogen Inc COM NEW maintained their buy rating.

There is no last upgrade for Histogen Inc COM NEW

There is no last downgrade for Histogen Inc COM NEW.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Histogen Inc COM NEW, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Histogen Inc COM NEW was filed on March 29, 2022 so you should expect the next rating to be made available sometime around March 29, 2023.

While ratings are subjective and will change, the latest Histogen Inc COM NEW (HSTO) rating was a maintained with a price target of $2.40 to $1.50. The current price Histogen Inc COM NEW (HSTO) is trading at is $0.22, which is out of the analyst’s predicted range.